English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Nearly two-thirds of all patients with prostate cancer in Sri Lanka present with systemic metastases (1). Since the seminal discovery of its effect by Huggins and Hodges in 1941, androgen deprivation therapy (ADT) has remained the bedrock in the management of metastatic prostate cancer (2). There has been a surge in the development of new therapeutic options in metastatic prostate cancer and this article reviews some of these recent advances from the perspective of clinical practice in Sri Lanka.

Management of metastatic prostate cancer: recent advances, clinical perspectives and future prospects